Kazal型蛋白酶抑制剂结构与功能研究进展

蛋白酶抑制剂广泛存在于生物体内,在许多生命活动过程中发挥必不可少的作用,特别是对蛋白酶活性进行精确调控。其中Kazal型蛋白酶抑制剂是最重要的、研究最为广泛的酶抑制剂之一,该类抑制剂一般由一个或几个结构域组成,每一个结构域具有保守的序列和分子构象,同时发现该类抑制剂与蛋白酶作用的结合部位高度易变,它们大多数暴露于与溶剂接触的环上,其中P1部位是抑制作用的关键部位,抑制剂的专一性由P1部位氨基酸残基的性质决定,其它残基取代结合部位残基对抑制剂-酶的结合常数有显著的影响。Laskowski算法可直接从Kazal型丝氨酸蛋白酶抑制剂的序列推测其与6种丝氨酸蛋白酶之间的抑制常数(Ki)。目前在生物体内发现大量的Kazal型蛋白酶抑制剂,并证实其有重要的生物学功能。     

几种蛋白酶活力测定新方法

几种蛋白酶活力测定新方法陈安和（西南师范大学生化教研室,重庆６３０７１５）关键词蛋白酶活力测定近年来,蛋白酶特别是丝氨酸蛋白酶及其抑制剂已成为研究热点。众多研究表明,蛋白酶在许多重要的生命活动过程中发挥着十分重要的作用。蛋白酶参与蛋白质的水解、消化、...     

Kunitz型丝氨酸蛋白酶抑制剂研究进展

Kunitz型丝氨酸蛋白酶抑制剂是一类普遍存在的蛋白酶抑制剂,在体内各项生命活动中扮演着重要角色。这类抑制剂结构稳定且富有特色,通常具有一个或几个串联存在的Kunitz结构域,能够以类似底物的方式与丝氨酸蛋白酶结合,从而抑制酶的活性。在功能方面,Kunitz型丝氨酸蛋白酶抑制剂参与凝血和纤维蛋白溶解、肿瘤免疫、炎症调节以及抵抗细菌、真菌感染等过程。文中就Kunitz型丝氨酸蛋白酶抑制剂研究进展作一综述,为新型Kunitz型丝氨酸蛋白酶抑制剂的开发提供研究思路。     

丙型肝炎病毒丝氨酸蛋白酶的研究进展

丙型肝炎病毒（ＨＣＶ）非结构３区（ＮＳ３）编码的丝氨酸蛋白酶是ＨＣＶ复制过程中的重要蛋白酶,负责对ＮＳ３、ＮＳ４及ＮＳ５进行加工。ＮＳ４ａ是ＨＣＶ丝氨酸蛋白酶作用的辅因子,并具有多种活性。ＨＣＶ丝氨酸蛋白酶有相对特异的底物,其活性不能被一般的丝氨酸蛋白抑制剂所抑制。丝氨酸蛋白酶是ＨＣＶ药物设计的靶目标之一。对其结构与功能的研究有着重要意义。     

SERPINE家族在纤维化疾病中作用的研究进展

丝氨酸蛋白酶抑制剂(Serine Protease Inhibitor,Serpin)是一类丝氨酸蛋白酶活性调节剂,在人体中被分为A~I9个亚家族,其中SERPINE(Serpin Peptidase Inhibitor,Clade E)家族参与调节生物体内多个重要的生命过程。本文通过介绍SERPINE家族中两个重要成员SERPINE1与SERPINE2的理化性质、作用机制以及调控因素,阐述SERPINE家族在纤维化相关疾病中的作用及研究进展。     

慈菇蛋白酶抑制剂研究进展

蛋白酶抑制剂是一类能够抑制蛋白水解酶活性的物质。根据它们抑制的蛋白酶类型可分为丝氨酸、半胱氨酸、天冬氨酸、和金属蛋白酶抑制剂[1] 。由于它们能抑制昆虫肠道内以及一些病原微生物体内的蛋白酶[2～ 6 ] ,因此蛋白酶抑制剂在植物对昆虫和病原体的侵染防御系统中具有重要的作用。慈菇蛋白酶抑制剂Ａ、Ｂ是从慈菇球茎中分离纯化的双头多功能蛋白酶抑制剂 ,除了具备其他蛋白酶抑制剂在抗虫抗病方面的特点外 ,还有很多独特的优点。如 ,含量丰富、比活力高而且稳定 ;广谱性强 ;对胰蛋白酶、胰凝乳蛋白酶、激肽释放酶等多种蛋白酶有较强的抑…     

蛋白酶抑制剂反应环区的结构研究

蛋白质分子表面环区常在蛋白质功能和行为中起重要作用.我们对一些丝氨酸蛋白酶抑制剂的反应环区和已知的限制性水解部位做了结构比较研究.研究结果表明,蛋白质抑制剂反应部位所处的环区具有独特的结构,使其能够对相应蛋白酶发挥很高的抑制作用.     

受染巨噬细胞释放的鼠伤寒沙门菌可灭活抗蛋白酶

鼠伤寒沙门菌经口进入消化道，穿过小肠上皮屏障侵入宿主。其重要特征是能在黏膜下层的巨噬细胞和树突细胞中繁殖，随之从胃肠道向肝、脾等网状内皮组织扩散。细菌迁移时，丝氨酸纤维蛋白酶在细胞外基质（ECM）降解过程中起重要作用。此酶由丝氨酸蛋白酶抑制剂α2AP负调控。沙门菌的表面蛋白酶PgtE可通过蛋白水解作用使α2AP失活，     

食线虫真菌致病相关丝氨酸蛋白酶的研究进展

食线虫真菌是一类土壤微生物,作为线虫的天敌,它们对于维持线虫在土壤生态环境中的种群动态平衡发挥着十分重要的作用。食线虫真菌通过形成特殊的捕食器官或产生毒素等方式来捕捉和杀死线虫。丝氨酸蛋白酶是食线虫真菌侵染线虫的重要毒力因子,近年来,研究人员对不同食线虫真菌来源的致病相关丝氨酸蛋白酶进行了大量的研究,尤其在丝氨酸蛋白酶的晶体结构和分子进化方面的研究取得了较大的进展。本文对食线虫真菌致病相关丝氨酸蛋白酶的生物化学性质和功能进行了系统的总结,对丝氨酸蛋白酶的晶体结构、催化机制及分子进化等最新的进展进行了评述。     

大豆蚜Kazal型丝氨酸蛋白酶抑制剂基因AgKaSPI对蜡蚧刺束梗孢菌侵染的表达响应

[目的]探究Kazal型丝氨酸蛋白酶抑制剂KaSPI在大豆蚜Aphis glycines的生长发育、消化和免疫防御等过程中的作用.[方法]基于大豆蚜转录组数据PCR克隆大豆蚜Kazal型丝氨酸蛋白酶抑制剂基因cDNA序列;qRT-PCR分别检测AgKaSPI在大豆蚜1-4龄若虫和成虫以及蜡蚧刺束梗孢菌Akanthomy...     

Protease nexin-2/amyloid beta-protein precursor in blood is a platelet-specific protein

The protease inhibitor, protease nexin-2 (PN-2), is the secreted form of the amyloid beta-protein precursor (APP) which contains the Kunitz protease inhibitor domain. PN-2/APP is an abundant platelet alpha-granule protein which is secreted upon platelet activation. PN-2/APP mRNA is present in cultured endothelial cells and the protein has been detected in plasma. In the present studies we quantitated PN-2/APP in platelets, plasma and several different cell types of the vasculature to identify the repository of the protein in the circulatory system. We report that PN-2/APP is predominantly a platelet protein in the vascular compartment. Lysates of unstimulated umbilical vein endothelial cells, granulocytes or monocytes contained little PN-2/APP based on sensitive functional protease binding and immunoblotting assays. Quantitative immunoblotting studies demonstrated that normal citrated-plasma contains less than or equal to 60 pM PN-2/APP. In contrast, platelets can contribute up to 30 nM PN-2/APP, indicating that they are the major source of the protein in blood.     

The neurite growth promoting protease nexin 1 in glial cells of the olfactory bulb of the gerbil: An ultrastructural study

The glia-derived serine protease inhibitor and neurite outgrowth promotor protease nexin-1 (PN-1) is expressed in Schwann cell precursors and astroblasts during embryogenesis. In the adult nervous system, PN-1 persists in the Schwann cells and olfactory glia only. Light-microscopic immunohistochemistry has revealed the presence of PN-1 in the olfactory mucosa and in the nerve fiber layer of the olfactory bulb. The present electron-microscopic study of the gerbil olfactory bulb confirms the occurrence of PN-1 in ensheathing cells of the olfactory nerve fiber layer, a special type of glia which envelops olfactory axons. In addition, PN-1 is contained in typical astrocytes of the nerve fiber layer and of the glomerular layer. It is inferred that synthesis of PN-1 in the olfactory bulbs is maintained throughout adulthood because its neurite outgrowth promoting action is required for the continuous renewal of olfactory receptor neurons.     

Inhibitors of Urokinase and Thrombin in Cultured Neural Cells

Recent studies have suggested important roles for certain proteases and protease inhibitors in the growth and development of the CNS. In the present studies, inhibitors of urokinase or thrombin in cultured neural cells and serum-free medium from the cells were identified by screening for components that formed sodium dodecyl sulfate-stable complexes with 125I-urokinase or 125I-thrombin. Rinsed glioblastoma possessed two components that complexed 125I-urokinase. One was type 1 plasminogen activator inhibitor (PAI-1), because the 125I-urokinase-containing complexes were immunoprecipitated with anti-PAI-1 antibodies. The other component formed complexes with 125I-urokinase that were not recognized by antibodies to PAI-1 or protease nexin-1 (PN-1). Its identity is unknown. In addition to these cell-bound components, the glioblastoma cells also secreted two inhibitors that formed complexes with 125I-urokinase; one was PAI-1, and the other was PN-1. The secreted PN-1 also formed complexes with 125I-thrombin. It was the only thrombin inhibitor detected in these studies. Human neuroblastoma cells did not contain components that formed detectable complexes with either 125I-urokinase or 125I-thrombin. However, human neuroblastoma cells did contain very low levels of PN-1 mRNA and PN-1 protein. Added PN-1 bound to the surface of both glioblastoma and neuroblastoma cells. This interaction accelerated the inhibition of thrombin by PN-1 and blocked the ability of PN-1 to form complexes with 125I-urokinase. Thus, cell-bound PN-1 was a specific thrombin inhibitor.(ABSTRACT TRUNCATED AT 250 WORDS)     

Protease nexin-1 complexes and inhibits T cell serine proteinase-1

The T cell serine proteinase-1 (TSP-1) which most probably is involved in cell killing by cytotoxic T cells is inhibited by protease nexin-1 (PN-1), an extravascular serine protease inhibitor. The inhibition is irreversible and correlates with formation of SDS-stable complexes between the two proteins. Two distinct species of complexes (91 and 122 kDa) are observed upon SDS-PAGE analysis of the reacted proteins, indicating that PN-1 is capable of complexing and inhibiting both subunits of the homodimeric TSP-1 molecule. Heparin (2 micrograms/ml) increases the association rate constant from 4.2 x 10(4) M-1 sec-1 to 4.8 x 10(5) M-1 sec-1. These observations suggest that PN-1 may function as a major extravascular inhibitor of TSP-1 released from cytotoxic T lymphocytes.     

High level expression, purification, and characterization of the Kunitz-type protease inhibitor domain of protease nexin-2/amyloid beta-protein precursor.

The protease inhibitor, protease nexin-2 (PN-2), is the secreted isoform of the Alzheimer's amyloid beta-protein precursor (A beta PP) that contains the Kunitz-type protease inhibitor (KPI) domain. Here we describe the use of the methylotrophic industrial yeast Pichia pastoris as a host system for the large scale production of the KPI domain of PN-2/A beta PP. In addition to the 57 amino acid KPI domain, the expression product contained an additional four amino acid residues at its amino terminus that correspond to amino acids 285-288 of A beta PP (Ponte et al. 1988 Nature 311:525-527). This expression system generated yields of greater than 1.0 gram of KPI domain per liter of fermentation media. The secreted 61 amino acid product was purified to homogeneity and biochemically characterized. Amino acid analysis and sequencing of the entire expressed KPI domain verified its integrity. Similar to native PN-2/A beta PP, the purified KPI domain potently inhibited trypsin, chymotrypsin, and coagulation factor XIa. Although heparin augments the inhibition of factor XIa by native PN-2/A beta PP it had no effect on the inhibition of factor XIa by expressed KPI domain suggesting that heparin binds to regions on native PN-2/A beta PP outside of the protease inhibitory domain. This KPI domain expression product should be useful in studying the physiologic and pathophysiologic functions of PN-2/A beta PP.     

Activation of ERK signaling upon alternative protease nexin-1 internalization mediated by syndecan-1

Protease nexin-1 (PN-1), an inhibitor of serine proteases, contributes to tissue homeostasis and influences the behavior of some tumor cells. The internalization of PN-1 protease complexes is considered to be mediated by the low-density lipoprotein receptor related protein 1 (LRP1). In this study, both wild-type and LRP1-/- mouse embryonic fibroblasts (MEF) were shown to internalize PN-1. Receptor associated protein (RAP) interfered with PN-1 uptake only in wild-type MEF cells, indicating that another receptor mediates PN-1 uptake in the absence of LRP1. In LRP1-/- MEF cells, inhibitor sensitivity and kinetic values (t(1/2) at 45 min) of PN-1 uptake showed a similarity to syndecan-1-mediated endocytosis. In these cells, PN-1 uptake was increased by overexpression of full-length syndecan-1 and decreased by RNA interference targeting this proteoglycan. Most important, in contrast to PKA activation known to be triggered by LRP1-mediated internalization, our study shows that syndecan-1-mediated internalization of PN-1 stimulated the Ras-ERK signaling pathway.     

Monoclonal antibodies to protease nexin 1 that differentially block its inhibition of target proteases

Protease nexin 1 (PN-1) is a protease inhibitor secreted by cultured fibroblasts that forms complexes with certain serine proteases; the complexes bind back to the cells and are internalized and degraded. In the present studies, a panel of PN-1 monoclonal antibodies (mAbs) was isolated; none showed detectable cross-reactivity with four related plasma protease inhibitors. Four purified mAbs (mAbp1, mAbp6, mAbp9, and mAbp18) were tested for their ability to block the formation of complexes between PN-1 and target proteases. mAbp1, as well as a rabbit polyclonal anti-PN-1 IgG preparation, did not block formation of 125I-thrombin-PN-1 complexes. mAbp6, mAbp9, and mAbp18 blocked the formation of 125I-thrombin-PN-1 and 125I-urokinase-PN-1 complexes at stoichiometric concentrations of mAb and PN-1. Studies on their ability to block formation of 125I-trypsin-PN-1 complexes showed that mAbp18 also blocked this reaction at stoichiometric concentrations with PN-1 whereas mAbp6 and mAbp9 blocked less effectively. Thus, mAbp18 appears to bind at or close to the reactive center of PN-1. The blocking mAbs should be useful in studies to probe physiological functions of PN-1.     

Inactivation of protease nexin-1 by xanthine oxidase-derived free radicals

Neuronal viability is affected by reactive oxygen species. Lipid peroxidation is often defined as a major reason for cellular breakdown. Additionally, certain indispensable proteins are possible targets for excessively formed reactive oxygen species. Evidence is given here that protease nexin-1(PN-1), an endogenous thrombin inhibitor and neurite outgrowth promoter, is inactivated by xanthine oxidase-derived free radicals. Varying protection by superoxide dismutase and catalase was observed, depending on the reaction conditions. The water-soluble a-tocopherol analogues MDL 74,406 (R(+)-3,4-dihydro-6-hydroxy-N,N,N- 2,5,7,8-heptamethyl-2H-1-benzopyran-2-ethanaminium 4-methylbenzenesulfonate), MDL 74,180DA (2,3- dihydro-2,2,4,6,7-pentamethyl-3-(4-methyl-piperazino)-1-benzofuran-5-ol dihydro-chloride) and trolox also protected PN-1. Neurodegeneration may be triggered by oxidative inactivation of protease inhibitors such as PN-1. Protection of PN-1 in Alzheimer's or Parkinson's diseases, could be a possible target for a therapeutic function of antioxidants in these diseases.     

Transforming growth factor-beta1 as a regulator of the serpins/t-PA axis in cerebral ischemia.

The tissue type plasminogen activator (t-PA) is a serine protease that is involved in neuronal plasticity and cell death induced by excitotoxins and ischemia in the brain. t-PA activity in the central nervous system is regulated through the activation of serine protease inhibitors (serpins) such as the plasminogen activator inhibitor (PAI-1), the protease nexin-1 (PN-1), and neuroserpin (NSP). Recently we demonstrated in vitro that PAI-1 produced by astrocytes mediates the neuroprotective effect of the transforming growth factor-beta1 (TGF-beta1) in NMDA-induced neuronal cell death. To investigate whether serpins may be involved in neuronal cell death after cerebral ischemia, we determined, by using semiquantitative RT-PCR and in situ hybridization, that focal cerebral ischemia in mice induced a dramatic overexpression of PAI-1 without any effect on PN-1, NSP, or t-PA. Then we showed that although the expression of PAI-1 is restricted to astrocytes, PN-1, NSP, and t-PA are expressed in both neurons and astrocytes. Moreover, by using semiquantitative RT-PCR and Western blotting, we observed that only the expression of PAI-1 was modulated by TGF-beta1 treatment via a TGF-beta-inducible element contained in the PAI-1 promoter (CAGA box). Finally, we compared the specificity of TGF-beta1 action with other members of the TGF-beta family by using luciferase reporter genes. These data show that TGF-beta and activin were able to induce the overexpression of PAI-1 in astrocytes, but that bone morphogenetic proteins, glial cell line-derived neutrophic factor, and neurturin did not. These results provide new insights into the regulation of the serpins/t-PA axis and the mechanism by which TGF-beta may be neuroprotective.